Your browser doesn't support javascript.
loading
Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate.
J Pediatr ; 109(1): 144-9, 1986 Jul.
Article in En | MEDLINE | ID: mdl-3088241
Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Dihydrotestosterone / Puberty / Gynecomastia Limits: Adolescent / Humans / Male Language: En Journal: J Pediatr Year: 1986 Document type: Article Country of publication: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Dihydrotestosterone / Puberty / Gynecomastia Limits: Adolescent / Humans / Male Language: En Journal: J Pediatr Year: 1986 Document type: Article Country of publication: United States